Cover Image
市場調查報告書

韋格納肉芽腫的預測:主要9大市場

Wegener's Granulomatosis Forecast in 9 Major Markets 2015-2025

出版商 Black Swan Analysis 商品編碼 339833
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
韋格納肉芽腫的預測:主要9大市場 Wegener's Granulomatosis Forecast in 9 Major Markets 2015-2025
出版日期: 2015年08月01日 內容資訊: 英文 42 Pages
簡介

韋格納肉芽腫是以多發性血管炎肉芽腫症知名的自體免疫疾病,包含ANCA相關血管炎的壞死性血管炎。

本報告提供主要9大市場 (美國,法國,德國,義大利,西班牙,英國,巴西,日本,印度) 的多發血管炎性肉芽腫症之目前患者數 (性別,年齡世代別) 調查分析,提供您目前得病率,加上危險因素,疾病診斷與預後,主要的症狀和併發症等系統性資訊。

圖表

概要

簡介

病因

危險因素和預防

疾病診斷

變異:地區/各民族

疾病預後與臨床經過

疾病相關的主要併發症/症候

患者數定量化手法

  • 追加資料

韋格納肉芽腫的得病率top line

韋格納肉芽腫的主要併發症·症候

  • 血管觀察
  • ANCA血清狀態
  • 韋格納肉芽腫的呼吸系統併發症
  • 韋格納肉芽腫的ENT症候
  • 韋格納肉芽腫的神經科的症候
  • 韋格納肉芽腫的腎障礙

參考文獻

附錄

目錄
Product Code: WEGG0010815

Wegener's Granulomatosis (WG), also known as granulomatous with polyangiitis, is an autoimmune disease, involving necrotizing vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). WG primarily involves the upper and lower respiratory tracts and kidneys and originates from an inherited genetic component coupled with an unknown environment stimulus. This report provides the current prevalent population for WG across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of WG have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for WG include:

  • Renal complications
  • Other autoimmune conditions
  • Respiratory complications
  • Neurological complications
  • Various vascular manifestations
  • Deafness

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global WG's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of WG and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on WG's prevalent population.
  • Identify sub-populations within WG which require treatment.
  • Gain an understanding of the specific markets that have the largest number of WG patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR, IN

Table of Contents

List of Tables & Figures

Overview

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Wegener's Granulomatosis

Main Complications and Presenting Features of Wegener's Granulomatosis

  • Vascular Manifestations
  • ANCA Serology Status
  • Respiratory Complications of Wegner's Granulomatosis
  • ENT Features of Wegner's Granulomatosis
  • Neurological Features of Wegner's Granulomatosis
  • Renal Involvement of Wegner's Granulomatosis

References

Appendix

List of Tables & Figures

  • Prevalence of WG, total (000s)
  • Prevalence of WG, males (000s)
  • Prevalence of WG, females (000s)
  • WG by vascular manifestation, total (000s)
  • ANCA serology status at presentation for WG, total (000s)
  • Respiratory infiltrates & effusions in patients with WG, total (000s)
  • Presence of lung inflammation in patients with WG, total (000s)
  • ENT features at presentation of patients with WG, total (000s)
  • Neurological involvement at presentation of patients with WG, total (000s)
  • Presence of abnormal glomeruli in patients with WG, total (000s)
  • USA Prevalence of WG by 5-yr age cohort, males (000s)
  • USA Prevalence of WG by 5-yr age cohort, females (000s)
  • France Prevalence of WG by 5-yr age cohort, males (000s)
  • France Prevalence of WG by 5-yr age cohort, females (000s)
  • Germany Prevalence of WG by 5-yr age cohort, males (000s)
  • Germany Prevalence of WG by 5-yr age cohort, females (000s)
  • Italy Prevalence of WG by 5-yr age cohort, males (000s)
  • Italy Prevalence of WG by 5-yr age cohort, females (000s)
  • Spain Prevalence of WG by 5-yr age cohort, males (000s)
  • Spain Prevalence of WG by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of WG by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of WG by 5-yr age cohort, females (000s)
  • Brazil Prevalence of WG by 5-yr age cohort, males (000s)
  • Brazil Prevalence of WG by 5-yr age cohort, females (000s)
  • Japan Prevalence of WG by 5-yr age cohort, males (000s)
  • Japan Prevalence of WG by 5-yr age cohort, females (000s)
  • India Prevalence of WG by 5-yr age cohort, males (000s)
  • India Prevalence of WG by 5-yr age cohort, females (000s)
Back to Top